Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 130 participants.

Also called NCT07273838

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 130 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07273838
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07273838. Randomized; quadruple masking; primary purpose treatment. Start 2026-03-05 (actual); primary completion 2028-08-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome
Condition
Heart Failure
Intervention (Drug)
Dapagliflozin 10mg Tab
Intervention (Drug)
Placebo
Lead sponsor
Yale University (class: other)
Collaborator
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (class: US National Institutes of Health)

Record details

Record id
cardio:ct-nct07273838
Content hash
8cc2deed0ece0c801e1af42c2989c0cb4b22fe0bba7d507ae9bd10bd40218a58